Drug intelligence / Profile preview

RPN301

Development stage: Unknown
Administration: Intravenous

Overview

RPN301 is an investigational drug evaluated in a phase 3 clinical trial for use in postoperative patients requiring central parenteral nutrition. The study compares the safety and efficacy of IN-C006 Peri inj. and RPN301, indicating that RPN301 is intended as a treatment option for patients needing parenteral nutritional support after surgery. Specific details regarding its mechanism of action, molecular modality, or developer are not provided in the available sources[5].

Beyond the preview

Go deeper on RPN301.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RPN301.

Explore the full profile